907P Biomarker analysis of the phase III KEYNOTE-040 study of pembrolizumab (pembro) versus methotrexate, docetaxel, or cetuximab (SOC) for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Annals of Oncology

Topics

Medicine

Cancer Oncology

Internal Medicine

Otorhinolaryngology

Pulmonary And Respiratory Medicine

Show all topics

DOI

10.1016/j.annonc.2024.08.968